Table I.
Patient Characteristics
| Pt | Age at Tx (years) | Sex | FAB | Cytogenetics | No of prior regimens | Prior BMT | Response to most recent therapy | Most recent therapy | Site of disease | Doses of MTX/Asp(type) | No. of courses | Response to MTX/Asp | Post-MTX/Asp transplant | Outcome (survival period) | Remission period | Cause of death |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1* | 3.4 | M | M2 | normal | 1 | relapse | ara-C/Asp | marrow | 60/10000 (E.coli) | 3 | CRi | haplo | alive (91 mo) | 90 mo | ||
| 2 | 10.5 | M | M5 | t(10;11) | 3 | MUD | refractory | clofarabine/ara-C | skin | 120/3000 (PEG) | 2 | CRi | alive (8.5 mo) | 8 mo | ||
| 3 | 1.1 | F | M5 | t(10;11) | 3 | refractory | clofarabine/ara-C | marrow,skin | 120/3000 (PEG) | 4 | CRi | UCBT | dead (4.5 mo) | 2 mo | disease | |
| 4 | 1.8 | F | M5 | t(10;11) | 2 | relapse | clofarabine/ara-C | marrow MRD | 100/10000 (E.coli) | 11 | PR | alloCBT | alive (57 mo) | 56 mo | ||
| 5 | 4.8 | F | M0 | normal | 1 | relapse | ara-C/Dauno/Eto | marrow | 120/3000 (PEG) | 4 | PR | alloBMT | alive (8.8 mo) | 8 mo | ||
| 6 | 11.3 | F | M1 | t(6;9) | 3 | refractory | hydroxyurea | marrow | 100/10000 (Erwinia) | 54 | stable disease | dead (16 mo) | disease | |||
| 7 | 18.5 | M | M4 | t(16;16) | 1 | relapse | cladribine/ara-C | marrow | 60/10000 (E.coli) | 2 | NR | dead (8.1 mo) | disease | |||
| 8 | 18.3 | M | M1 | normal | 4 | refractory | cladribine/ara-C | marrow | 60/10000 (E.coli) | 2 | NR | haplo | dead (16.5 mo) | disease | ||
| 9 | 15.8 | M | M4 | gain 5p | 4 | MSD | relapse | mitoxantrone/ara-C/GO | marrow | 100/2500 (PEG) | 1 | NR | dead (1.5 mo) | disease | ||
| 10 | 1.1 | M | M5 | t(3;11) | 3 | refractory | cladribine/ara-C | marrow | 100/10000 (E.coli) | 1 | NR | dead (1.4 mo) | disease | |||
| 11 | 2.9 | M | M7 | t(2;21;3) | 3 | haplo | refractory | BMT | marrow | 100/2500 (PEG) | 3 | NR | haplo | dead (8.5 mo) | disease | |
| 12 | 1.2 | M | M7 | t(9;11) | 2 | refractory | clofarabine/ara-C | marrow | 60/10000 (E.coli) | 2 | NR | dead (1.4 mo) | disease | |||
| 13 | 12 | M | M5 | t(6;11) | 3 | MSD | relapse | clofarabine/ara-C | marrow,skin | 120/3000 (PEG) | 1 | NR | dead (0.6 mo) | disease | ||
| 14 | 16.1 | M | M5 | t(10;11) | 3 | relapse | ara-C/idarubicin | marrow | 120/10000 (Erwinia) | 2 | NR | UCBT | dead (2.7 mo) | TRM due to BMT | ||
| 15 | 16.7 | M | M7 | t(3;21) | 3 | haplo | relapse | BMT | marrow | 120/3000 (PEG) | 1 | NR | dead (1.0 mo) | disease |
Abbreviations: ara-C, cytarabine; Asp, asparaginase; BM, bone marrow; BMT, bone marrow transplantation; CR, complete remission; CRi, morphologic complete remission with incomplete blood count recovery; Dauno, daunorubicin; Dx, diagnosis; Eto, etoposide; F, female; FAB, The French–American–British (FAB) classification; GO, gemtuzumab ozogamicin; haplo, haplo identical transplantation; M, male; mo, months; MRD, minimal residual disease; MSD, match sibling donor transplantation; MTX, methotrexate; MUD, match unrelated donor transplantation; NR, no response; PEG, polyethylene glycol- L –asparaginase; PR, partial response; Pt, patient; TRM, treatment related mortality; Tx, treatment with methotrexate/asparaginase; UCBT, umbilical cord blood transplantation.
Patient who received escalated doses of methotrexate.